| Year |
Citation |
Score |
| 2024 |
Barisic S, Cherkasova E, Nadal R, Tian X, Chen L, Parrizzi A, Reger RN, Scurti GM, Nishimura MI, Childs RW. Quantification of circulating TCR-engineered T cells targeting a human endogenous retrovirus post-adoptive transfer using nanoplate digital PCR. Molecular Therapy. Methods & Clinical Development. 32: 101324. PMID 39319301 DOI: 10.1016/j.omtm.2024.101324 |
0.53 |
|
| 2024 |
Barisic S, Brahmbhatt EM, Cherkasova E, Spear TT, Savani U, Pierre S, Scurti GM, Chen L, Igboko M, Nadal R, Zeng G, Parry G, Stroncek DF, Highfill S, Dalheim AV, ... ... Nishimura MI, et al. Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus. Journal For Immunotherapy of Cancer. 12. PMID 39266213 DOI: 10.1136/jitc-2024-009147 |
0.497 |
|
| 2023 |
Wang SY, Scurti G, Dalheim AV, Quinn SK, Stiff PJ, Nishimura MI. Nonactivated and IL-7 cultured CD19-specific CAR T cells are enriched in stem cell phenotypes and functionally superior. Blood Advances. PMID 37967375 DOI: 10.1182/bloodadvances.2023010607 |
0.602 |
|
| 2023 |
Gao X, Wu Y, Chick JM, Abbott A, Jiang B, Wang DJ, Comte-Walters S, Johnson RH, Oberholtzer N, Nishimura MI, Gygi SP, Mehta A, Guttridge DC, Ball L, Mehrotra S, et al. Targeting protein tyrosine phosphatases for CDK6-induced immunotherapy resistance. Cell Reports. 42: 112314. PMID 37000627 DOI: 10.1016/j.celrep.2023.112314 |
0.47 |
|
| 2022 |
Singh NK, Alonso JA, Devlin JR, Keller GLJ, Gray GI, Chiranjivi AK, Foote SG, Landau LM, Arbuiso AG, Weiss LI, Rosenberg AM, Hellman LM, Nishimura MI, Baker BM. A class-mismatched TCR bypasses MHC restriction via an unorthodox but fully functional binding geometry. Nature Communications. 13: 7189. PMID 36424374 DOI: 10.1038/s41467-022-34896-0 |
0.463 |
|
| 2022 |
Quinn S, Lenart N, Dronzek V, Scurti GM, Hossain NM, Nishimura MI. Genetic Modification of T Cells for the Immunotherapy of Cancer. Vaccines. 10. PMID 35335089 DOI: 10.3390/vaccines10030457 |
0.565 |
|
| 2022 |
Vuchkovska A, Glanville DG, Scurti GM, Nishimura MI, White P, Ulijasz AT, Iwashima M. Siglec-5 is an inhibitory immune checkpoint molecule for human T cells. Immunology. PMID 35290663 DOI: 10.1111/imm.13470 |
0.597 |
|
| 2021 |
Wang SY, Moore TV, Dalheim AV, Scurti GM, Nishimura MI. Melanoma reactive TCR-modified T cells generated without activation retain a less differentiated phenotype and mediate a superior in vivo response. Scientific Reports. 11: 13327. PMID 34172810 DOI: 10.1038/s41598-021-92808-6 |
0.584 |
|
| 2021 |
Moore TV, Scurti GM, DeJong M, Wang SY, Dalheim AV, Wagner CR, Hutchens KA, Speiser JJ, Godellas CV, Fountain C, Fleser J, Moudgil T, Thomas M, Murray D, Curti BD, ... ... Nishimura MI, et al. HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells. Molecular Therapy Oncolytics. 20: 352-363. PMID 33614916 DOI: 10.1016/j.omto.2021.01.014 |
0.605 |
|
| 2021 |
Lee JG, Jaeger KE, Seki Y, Lim YW, Cunha C, Vuchkovska A, Nelson AJ, Nikolai A, Kim D, Nishimura M, Knight KL, White P, Iwashima M. Human CD36 monocytes induce Foxp3 CD25 T cells with regulatory functions from CD4 and CD8 subsets. Immunology. PMID 33524161 DOI: 10.1111/imm.13316 |
0.573 |
|
| 2020 |
Nelson MH, Knochelmann HM, Bailey SR, Huff LW, Bowers JS, Majchrzak-Kuligowska K, Wyatt MM, Rubinstein MP, Mehrotra S, Nishimura MI, Armeson KE, Giresi PG, Zilliox MJ, Broxmeyer HE, Paulos CM. Identification of human CD4 T cell populations with distinct antitumor activity. Science Advances. 6. PMID 32937437 DOI: 10.1126/Sciadv.Aba7443 |
0.687 |
|
| 2020 |
Pulido I, Ollosi S, Aparisi S, Becker JH, Aliena-Valero A, Benet M, Rodríguez ML, López A, Tamayo-Torres E, Chuliá-Peris L, García-Cañaveras JC, Soucheray M, Dalheim AV, Salom JB, Qiu W, ... ... Nishimura MI, et al. Endothelin-1-mediated Drug Resistance in EGFR-mutant NSCLC. Cancer Research. PMID 32747363 DOI: 10.1158/0008-5472.Can-20-0141 |
0.331 |
|
| 2020 |
Smith TW, Nishimura MI. Targeting Cancer with Genetically Engineered TCR T Cells. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer. 214: 129-151. PMID 31473851 DOI: 10.1007/978-3-030-23765-3_4 |
0.555 |
|
| 2020 |
Nelson MH, Knochelmann HM, Bailey SR, Huff LW, Bowers JS, Majchrzak-Kuligowska K, Wyatt MM, Rubinstein MP, Mehrotra S, Nishimura MI, Armeson KE, Giresi PG, Zilliox MJ, Broxmeyer HE, Paulos CM. Identification of human CD4+ T cell populations with distinct antitumor activity Science Advances. 6: eaba7443. DOI: 10.1126/sciadv.aba7443 |
0.604 |
|
| 2019 |
Spear TT, Evavold BD, Baker BM, Nishimura MI. Understanding TCR affinity, antigen specificity, and cross-reactivity to improve TCR gene-modified T cells for cancer immunotherapy. Cancer Immunology, Immunotherapy : Cii. PMID 31595324 DOI: 10.1007/S00262-019-02401-0 |
0.629 |
|
| 2019 |
Kierkels GJJ, Scheper W, Meringa AD, Johanna I, Beringer DX, Janssen A, Schiffler M, Aarts-Riemens T, Kramer L, Straetemans T, Heijhuurs S, Leusen JHW, San José E, Fuchs K, Griffioen M, ... ... Nishimura MI, et al. Identification of a tumor-specific allo-HLA-restricted γδTCR. Blood Advances. 3: 2870-2882. PMID 31585951 DOI: 10.1182/Bloodadvances.2019032409 |
0.497 |
|
| 2019 |
Cosgrove C, Dellacecca ER, van den Berg JH, Haanen JB, Nishimura MI, Le Poole IC, Bergmans HEN. Transgenerational transfer of gene-modified T cells. Journal For Immunotherapy of Cancer. 7: 186. PMID 31307533 DOI: 10.1186/S40425-019-0657-2 |
0.595 |
|
| 2019 |
Chakraborty P, Chatterjee S, Kesarwani P, Thyagarajan K, Iamsawat S, Dalheim A, Nguyen H, Selvam SP, Nasarre P, Scurti G, Hardiman G, Maulik N, Ball LE, Gangaraju V, Rubinstein MP, ... ... Nishimura MI, et al. Thioredoxin-1 improves the immuno-metabolic phenotype of anti-tumor T cells. The Journal of Biological Chemistry. PMID 30971427 DOI: 10.1074/Jbc.Ra118.006753 |
0.605 |
|
| 2019 |
Breuer EK, Fukushiro-Lopes D, Dalheim A, Burnette M, Zartman J, Kaja S, Wells C, Campo L, Curtis KJ, Romero-Moreno R, Littlepage LE, Niebur GL, Hoskins K, Nishimura MI, Gentile S. Potassium channel activity controls breast cancer metastasis by affecting β-catenin signaling. Cell Death & Disease. 10: 180. PMID 30792401 DOI: 10.1038/S41419-019-1429-0 |
0.32 |
|
| 2018 |
Hellman LM, Foley KC, Singh NK, Alonso JA, Riley TP, Devlin JR, Ayres CM, Keller GLJ, Zhang Y, Vander Kooi CW, Nishimura MI, Baker BM. Improving T Cell Receptor On-Target Specificity via Structure-Guided Design. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 30617019 DOI: 10.1016/J.Ymthe.2018.12.010 |
0.497 |
|
| 2018 |
Riley TP, Hellman LM, Gee MH, Mendoza JL, Alonso JA, Foley KC, Nishimura MI, Vander Kooi CW, Garcia KC, Baker BM. T cell receptor cross-reactivity expanded by dramatic peptide-MHC adaptability. Nature Chemical Biology. 14: 934-942. PMID 30224695 DOI: 10.1038/S41589-018-0130-4 |
0.541 |
|
| 2018 |
Eby JM, Smith AR, Riley TP, Cosgrove C, Ankney CM, Henning SW, Paulos CM, Garrett-Mayer E, Luiten RM, Nishimura MI, Baker BM, Le Poole IC. Molecular properties of gp100-reactive T cell receptors drive the cytokine profile and antitumor efficacy of transgenic host T cells. Pigment Cell & Melanoma Research. PMID 30009548 DOI: 10.1111/Pcmr.12724 |
0.66 |
|
| 2018 |
Nelson A, Cunha C, Nishimura MI, Iwashima M. Activated human Foxp3 regulatory T cells produce membrane-bound TNF. Cytokine. PMID 29885993 DOI: 10.1016/J.Cyto.2018.05.036 |
0.466 |
|
| 2018 |
Foley KC, Nishimura MI, Moore TV. Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma. Melanoma Research. PMID 29521881 DOI: 10.1097/Cmr.0000000000000436 |
0.453 |
|
| 2018 |
Spear TT, Wang Y, Smith TW, Simms PE, Garrett-Mayer E, Hellman LM, Baker BM, Nishimura MI. Altered Peptide Ligands Impact the Diversity of Polyfunctional Phenotypes in T Cell Receptor Gene-Modified T Cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 29503203 DOI: 10.1016/J.Ymthe.2018.01.015 |
0.626 |
|
| 2018 |
Scheffel MJ, Scurti G, Wyatt MM, Garrett-Mayer E, Paulos CM, Nishimura MI, Voelkel-Johnson C. N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner. Cancer Immunology, Immunotherapy : Cii. PMID 29396710 DOI: 10.1007/S00262-018-2120-5 |
0.656 |
|
| 2018 |
Spear TT, Foley KC, Garrett-Mayer E, Nishimura MI. TCR modifications that enhance chain pairing in gene-modified T cells can augment cross-reactivity and alleviate CD8 dependence. Journal of Leukocyte Biology. PMID 29350789 DOI: 10.1002/Jlb.5A0817-314R |
0.578 |
|
| 2018 |
Jacks RD, Keller TJ, Nelson A, Nishimura MI, White P, Iwashima M. Cell intrinsic characteristics of human cord blood naïve CD4T cells. Immunology Letters. 193: 51-57. PMID 29180044 DOI: 10.1016/J.Imlet.2017.11.011 |
0.543 |
|
| 2017 |
Moore T, Wagner CR, Scurti GM, Hutchens KA, Godellas C, Clark AL, Kolawole EM, Hellman LM, Singh NK, Huyke FA, Wang SY, Calabrese KM, Embree HD, Orentas R, Shirai K, ... ... Nishimura MI, et al. Correction to: Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. Cancer Immunology, Immunotherapy : Cii. PMID 29264697 DOI: 10.1007/S00262-017-2102-Z |
0.494 |
|
| 2017 |
Sandri S, De Sanctis F, Lamolinara A, Boschi F, Poffe O, Trovato R, Fiore A, Sartori S, Sbarbati A, Bondanza A, Cesaro S, Krampera M, Scupoli MT, Nishimura MI, Iezzi M, et al. Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy. Oncotarget. 8: 86987-87001. PMID 29152058 DOI: 10.18632/Oncotarget.18115 |
0.54 |
|
| 2017 |
Chatterjee S, Daenthanasanmak A, Chakraborty P, Wyatt MW, Dhar P, Selvam SP, Fu J, Zhang J, Nguyen H, Kang I, Toth K, Al-Homrani M, Husain M, Beeson G, Ball L, ... ... Nishimura MI, et al. CD38-NAD(+)Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response. Cell Metabolism. PMID 29129787 DOI: 10.1016/J.Cmet.2017.10.006 |
0.618 |
|
| 2017 |
Moore T, Wagner CR, Scurti GM, Hutchens KA, Godellas C, Clark AL, Kolawole EM, Hellman LM, Singh NK, Huyke FA, Wang SY, Calabrese KM, Embree HD, Orentas R, Shirai K, ... ... Nishimura MI, et al. Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. Cancer Immunology, Immunotherapy : Cii. PMID 29052782 DOI: 10.1007/S00262-017-2073-0 |
0.612 |
|
| 2017 |
Muller L, Simms P, Hong CS, Nishimura MI, Jackson EK, Watkins SC, Whiteside TL. Human tumor-derived exosomes (TEX) regulate Treg functions via cell surface signaling rather than uptake mechanisms. Oncoimmunology. 6: e1261243. PMID 28919985 DOI: 10.1080/2162402X.2016.1261243 |
0.561 |
|
| 2017 |
Wrangle J, Paulos CM, Smith TW, Nishimura MI, Rubinstein MP. Inducible Enhancement of T Cell Function and Anti-tumor Activity after Adoptive Transfer. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 28830671 DOI: 10.1016/J.Ymthe.2017.08.002 |
0.564 |
|
| 2017 |
Spear TT, Wang Y, Foley KC, Murray DC, Scurti GM, Simms PE, Garrett-Mayer E, Hellman LM, Baker BM, Nishimura MI. Critical biological parameters modulate affinity as a determinant of function in T-cell receptor gene-modified T-cells. Cancer Immunology, Immunotherapy : Cii. PMID 28634816 DOI: 10.1007/S00262-017-2032-9 |
0.634 |
|
| 2017 |
Sandri S, De Sanctis F, Lamolinara A, Boschi F, Poffe O, Trovato R, Fiore A, Sartori S, Sbarbati A, Bondanza A, Cesaro S, Krampera M, Scupoli MT, Nishimura MI, Iezzi M, et al. Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy. Oncotarget. PMID 28586310 DOI: 10.18632/oncotarget.18115 |
0.454 |
|
| 2017 |
Foley KC, Spear TT, Murray DC, Nagato K, Garrett-Mayer E, Nishimura MI. HCV T Cell Receptor Chain Modifications to Enhance Expression, Pairing, and Antigen Recognition in T Cells for Adoptive Transfer. Molecular Therapy Oncolytics. 5: 105-115. PMID 28573185 DOI: 10.1016/J.Omto.2017.05.004 |
0.618 |
|
| 2017 |
Wang Y, Singh NK, Spear TT, Hellman LM, Piepenbrink KH, McMahan RH, Rosen HR, Vander Kooi CW, Nishimura MI, Baker BM. How an alloreactive T-cell receptor achieves peptide and MHC specificity. Proceedings of the National Academy of Sciences of the United States of America. PMID 28572406 DOI: 10.1073/Pnas.1700459114 |
0.422 |
|
| 2017 |
Spear TT, Nishimura MI, Simms PE. Comparative exploration of multidimensional flow cytometry software: a model approach evaluating T cell polyfunctional behavior. Journal of Leukocyte Biology. PMID 28550117 DOI: 10.1189/Jlb.6A0417-140R |
0.364 |
|
| 2017 |
Mehrotra S, Britten CD, Chin S, Garrett-Mayer E, Cloud CA, Li M, Scurti G, Salem ML, Nelson MH, Thomas MB, Paulos CM, Salazar AM, Nishimura MI, Rubinstein MP, Li Z, et al. Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. Journal of Hematology & Oncology. 10: 82. PMID 28388966 DOI: 10.1186/S13045-017-0459-2 |
0.375 |
|
| 2017 |
Wang S, Scurti G, Dalheim A, Moore T, Nishimura M. Utilizing IL-7 to generate melanoma antigen T cell receptor-modified cells for adoptive transfer in the absence of activation. Journal of Clinical Oncology. 35: e14552-e14552. DOI: 10.1200/JCO.2017.35.15_SUPPL.E14552 |
0.463 |
|
| 2016 |
Kesarwani P, Chakraborty P, Gudi R, Chatterjee S, Scurti G, Toth K, Simms P, Husain M, Armeson K, Husain S, Garrett-Mayer E, Vasu C, Nishimura MI, Mehrotra S. Blocking TCR restimulation induced necroptosis in adoptively transferred T cells improves tumor control. Oncotarget. PMID 27750220 DOI: 10.18632/Oncotarget.12674 |
0.652 |
|
| 2016 |
Scheffel MJ, Scurti G, Simms P, Garrett-Mayer E, Mehrotra S, Nishimura MI, Voelkel-Johnson C. Efficacy of Adoptive T-cell Therapy Is Improved by Treatment with the Antioxidant N-Acetyl Cysteine, Which Limits Activation-Induced T-cell Death. Cancer Research. 76: 6006-6016. PMID 27742673 DOI: 10.1158/0008-5472.Can-16-0587 |
0.647 |
|
| 2016 |
Banerjee A, Thyagarajan K, Chatterjee S, Chakraborty P, Kesarwani P, Soloshchenko M, Hommrani MA, Andrijauskaite K, Moxley K, Janakiraman H, Scheffel MJ, Helke K, Armeson K, Palanisamy V, Rubinstein MP, ... ... Nishimura MI, et al. Lack of p53 Augments Anti-Tumor Functions In Cytolytic T Cells. Cancer Research. PMID 27466285 DOI: 10.1158/0008-5472.Can-15-1798 |
0.63 |
|
| 2016 |
Sandri S, Bobisse S, Moxley K, Lamolinara A, De Sanctis F, Boschi F, Sbarbati A, Fracasso G, Ferrarini G, Hendriks RW, Cavallini C, Scupoli MT, Sartoris S, Iezzi M, Nishimura MI, et al. Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies. Cancer Research. 76: 2540-51. PMID 27197263 DOI: 10.1158/0008-5472.Can-15-2318 |
0.624 |
|
| 2016 |
Spear TT, Nagato K, Nishimura MI. Strategies to genetically engineer T cells for cancer immunotherapy. Cancer Immunology, Immunotherapy : Cii. PMID 27138532 DOI: 10.1007/S00262-016-1842-5 |
0.587 |
|
| 2016 |
Spear TT, Riley TP, Lyons GE, Callender GG, Roszkowski JJ, Wang Y, Simms PE, Scurti GM, Foley KC, Murray DC, Hellman LM, McMahan RH, Iwashima M, Garrett-Mayer E, Rosen HR, ... ... Nishimura MI, et al. Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability. Journal of Leukocyte Biology. PMID 26921345 DOI: 10.1189/Jlb.2A1215-561R |
0.563 |
|
| 2016 |
Hellman LM, Yin L, Wang Y, Blevins SJ, Riley TP, Belden OS, Spear TT, Nishimura MI, Stern LJ, Baker BM. Differential scanning fluorimetry based assessments of the thermal and kinetic stability of peptide-MHC complexes. Journal of Immunological Methods. PMID 26906089 DOI: 10.1016/J.Jim.2016.02.016 |
0.344 |
|
| 2016 |
Blevins SJ, Pierce BG, Singh NK, Riley TP, Wang Y, Spear TT, Nishimura MI, Weng Z, Baker BM. How structural adaptability exists alongside HLA-A2 bias in the human αβ TCR repertoire. Proceedings of the National Academy of Sciences of the United States of America. PMID 26884163 DOI: 10.1073/Pnas.1522069113 |
0.388 |
|
| 2016 |
Spear TT, Callender GG, Roszkowski JJ, Moxley KM, Simms PE, Foley KC, Murray DC, Scurti GM, Li M, Thomas JT, Langerman A, Garrett-Mayer E, Zhang Y, Nishimura MI. TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors. Cancer Immunology, Immunotherapy : Cii. PMID 26842125 DOI: 10.1007/S00262-016-1800-2 |
0.427 |
|
| 2016 |
Klarquist J, Eby JM, Henning SW, Li M, Wainwright DA, Westerhof W, Luiten RM, Nishimura MI, Le Poole IC. Functional cloning of a gp100-reactive T cell receptor from vitiligo patient skin. Pigment Cell & Melanoma Research. PMID 26824221 DOI: 10.1111/Pcmr.12458 |
0.583 |
|
| 2015 |
Takami M, Fujimaki K, Nishimura MI, Iwashima M. Cutting Edge: AhR Is a Molecular Target of Calcitriol in Human T Cells. Journal of Immunology (Baltimore, Md. : 1950). 195: 2520-3. PMID 26276877 DOI: 10.4049/Jimmunol.1500344 |
0.459 |
|
| 2015 |
You D, Xin J, Volk A, Wei W, Schmidt R, Scurti G, Nand S, Breuer EK, Kuo PC, Breslin P, Kini AR, Nishimura MI, Zeleznik-Le NJ, Zhang J. FAK mediates a compensatory survival signal parallel to PI3K-AKT in PTEN-null T-ALL cells. Cell Reports. 10: 2055-68. PMID 25801032 DOI: 10.1016/J.Celrep.2015.02.056 |
0.505 |
|
| 2015 |
Regan C, Clark J, Moore T, Moxley K, Scurti G, Lau Clark A, Dropulic B, Embree H, Shirai K, Garrett-Mayer E, Li M, Tobin Vealey K, Eby JM, Le Poole C, Nishimura M. T-cell therapy in metastatic melanoma: TIL 1383I TCR transduced T cells after infusion and activity in vivo. Journal of Clinical Oncology. 33: 3043-3043. DOI: 10.1200/Jco.2015.33.15_Suppl.3043 |
0.598 |
|
| 2015 |
Regan C, Nishimura M, Le Poole IC, Godellas C, Stiff P, Garrett-Mayer E, Li M, Shirai K, Eby J, Embree H, Dropulic B, Clark AL, Hutchens K, Clark JI. The transfer of genetically engineered lymphocytes in melanoma patients: a Phase I dose escalation study Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P168 |
0.483 |
|
| 2015 |
Muller L, Simms P, Nishimura M, Watkins S, Whiteside T. 18 Surface binding followed by Ca2+ influx results in selective activation of human regulatory T cells (Treg) by tumor-derived exosomes (TEX) Oral Oncology. 51: e33. DOI: 10.1016/j.oraloncology.2015.02.020 |
0.377 |
|
| 2014 |
Kesarwani P, Al-Khami AA, Scurti G, Thyagarajan K, Kaur N, Husain S, Fang Q, Naga OS, Simms P, Beeson G, Voelkel-Johnson C, Garrett-Mayer E, Beeson CC, Nishimura MI, Mehrotra S. Promoting thiol expression increases the durability of antitumor T-cell functions. Cancer Research. 74: 6036-47. PMID 25164014 DOI: 10.1158/0008-5472.Can-14-1084 |
0.674 |
|
| 2014 |
Eby JM, Kang HK, Klarquist J, Chatterjee S, Mosenson JA, Nishimura MI, Garrett-Mayer E, Longley BJ, Engelhard VH, Mehrotra S, Le Poole IC. Immune responses in a mouse model of vitiligo with spontaneous epidermal de- and repigmentation. Pigment Cell & Melanoma Research. 27: 1075-85. PMID 24935676 DOI: 10.1111/Pcmr.12284 |
0.501 |
|
| 2014 |
Chatterjee S, Eby JM, Al-Khami AA, Soloshchenko M, Kang HK, Kaur N, Naga OS, Murali A, Nishimura MI, Le Poole IC, Mehrotra S. A quantitative increase in regulatory T cells controls development of vitiligo. The Journal of Investigative Dermatology. 134: 1285-94. PMID 24366614 DOI: 10.1038/Jid.2013.540 |
0.498 |
|
| 2013 |
Mosenson JA, Zloza A, Nieland JD, Garrett-Mayer E, Eby JM, Huelsmann EJ, Kumar P, Denman CJ, Lacek AT, Kohlhapp FJ, Alamiri A, Hughes T, Bines SD, Kaufman HL, Overbeck A, ... ... Nishimura MI, et al. Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Science Translational Medicine. 5: 174ra28. PMID 23447019 DOI: 10.1126/Scitranslmed.3005127 |
0.516 |
|
| 2013 |
Regan C, Nishimura M, Clark AL, Moxley K, Scurti G, Slepushkin V, Roy A, Schonely K, Dropulic B, Clark J. Genetically engineered lymphocytes in metastatic melanoma: TIL 1383I TCR transduced T-cells are detectable after infusion Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P31 |
0.407 |
|
| 2012 |
Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, ... ... Nishimura MI, et al. Cancer classification using the Immunoscore: a worldwide task force. Journal of Translational Medicine. 10: 205. PMID 23034130 DOI: 10.1186/1479-5876-10-205 |
0.368 |
|
| 2012 |
Mehrotra S, Al-Khami AA, Klarquist J, Husain S, Naga O, Eby JM, Murali AK, Lyons GE, Li M, Spivey ND, Norell H, Martins da Palma T, Onicescu G, Diaz-Montero CM, Garrett-Mayer E, ... ... Nishimura MI, et al. A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice. Journal of Immunology (Baltimore, Md. : 1950). 189: 1627-38. PMID 22798675 DOI: 10.4049/Jimmunol.1103271 |
0.763 |
|
| 2011 |
Al-Khami AA, Mehrotra S, Nishimura MI. Adoptive immunotherapy of cancer: Gene transfer of T cell specificity. Self/Nonself. 2: 80-84. PMID 22299059 DOI: 10.4161/self.2.2.15832 |
0.546 |
|
| 2011 |
Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, ... ... Nishimura MI, et al. Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine. 9: 214. PMID 22168571 DOI: 10.1186/1479-5876-9-214 |
0.301 |
|
| 2011 |
Zloza A, Jagoda MC, Lyons GE, Graves MC, Kohlhapp FJ, O'Sullivan JA, Lacek AT, Nishimura MI, Guevara-Patiño JA. CD8 co-receptor promotes susceptibility of CD8+ T cells to transforming growth factor-β (TGF-β)-mediated suppression. Cancer Immunology, Immunotherapy : Cii. 60: 291-7. PMID 21193909 DOI: 10.1007/S00262-010-0962-6 |
0.528 |
|
| 2011 |
Mimura K, Ando T, Poschke I, Mougiakakos D, Johansson CC, Ichikawa J, Okita R, Nishimura MI, Handke D, Krug N, Choudhury A, Seliger B, Kiessling R. T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2. International Journal of Cancer. Journal International Du Cancer. 128: 390-401. PMID 20715101 DOI: 10.1002/Ijc.25613 |
0.456 |
|
| 2010 |
McMahan RH, Golden-Mason L, Nishimura MI, McMahon BJ, Kemper M, Allen TM, Gretch DR, Rosen HR. Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. The Journal of Clinical Investigation. 120: 4546-57. PMID 21084749 DOI: 10.1172/Jci43127 |
0.411 |
|
| 2010 |
Zhang Y, Liu Y, Moxley KM, Golden-Mason L, Hughes MG, Liu T, Heemskerk MH, Rosen HR, Nishimura MI. Transduction of human T cells with a novel T-cell receptor confers anti-HCV reactivity. Plos Pathogens. 6: e1001018. PMID 20686664 DOI: 10.1371/Journal.Ppat.1001018 |
0.426 |
|
| 2010 |
Brusko TM, Koya RC, Zhu S, Lee MR, Putnam AL, McClymont SA, Nishimura MI, Han S, Chang LJ, Atkinson MA, Ribas A, Bluestone JA. Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. Plos One. 5: e11726. PMID 20668510 DOI: 10.1371/Journal.Pone.0011726 |
0.624 |
|
| 2010 |
Koya RC, Mok S, Comin-Anduix B, Chodon T, Radu CG, Nishimura MI, Witte ON, Ribas A. Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses. Proceedings of the National Academy of Sciences of the United States of America. 107: 14286-91. PMID 20624956 DOI: 10.1073/Pnas.1008300107 |
0.573 |
|
| 2010 |
Klarquist J, Denman CJ, Hernandez C, Wainwright DA, Wainwright DJ, Strickland FM, Overbeck A, Mehrotra S, Nishimura MI, Le Poole IC. Reduced skin homing by functional Treg in vitiligo. Pigment Cell & Melanoma Research. 23: 276-86. PMID 20175879 DOI: 10.1111/J.1755-148X.2010.00688.X |
0.495 |
|
| 2010 |
Norell H, Zhang Y, McCracken J, Martins da Palma T, Lesher A, Liu Y, Roszkowski JJ, Temple A, Callender GG, Clay T, Orentas R, Guevara-Patiño J, Nishimura MI. CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting. Cancer Immunology, Immunotherapy : Cii. 59: 851-62. PMID 20052466 DOI: 10.1007/S00262-009-0810-8 |
0.787 |
|
| 2010 |
Brusko T, Koya R, Zhu S, Lee M, Putnam A, McClymont S, Nishimura M, Xia N, Bluestone J. Lentiviral TCR-engineered Tregs Demonstrate Effective Suppression of T Cell Responses Clinical Immunology. 135: S30. DOI: 10.1016/J.Clim.2010.03.093 |
0.454 |
|
| 2009 |
Klarquist J, Barfuss A, Kandala S, Reust MJ, Braun RK, Hu J, Dilling DF, McKee MD, Boissy RE, Love RB, Nishimura MI, Le Poole IC. Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells. The American Journal of Pathology. 175: 2463-72. PMID 19893037 DOI: 10.2353/Ajpath.2009.090525 |
0.64 |
|
| 2009 |
Norell H, Martins da Palma T, Lesher A, Kaur N, Mehrotra M, Naga OS, Spivey N, Olafimihan S, Chakraborty NG, Voelkel-Johnson C, Nishimura MI, Mukherji B, Mehrotra S. Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death. Cancer Research. 69: 6282-9. PMID 19638595 DOI: 10.1158/0008-5472.Can-09-1176 |
0.766 |
|
| 2009 |
Voelkl S, Moore TV, Rehli M, Nishimura MI, Mackensen A, Fischer K. Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination. Cancer Immunology, Immunotherapy : Cii. 58: 709-18. PMID 18836718 DOI: 10.1007/S00262-008-0593-3 |
0.68 |
|
| 2009 |
Moore TV, Lyons GE, Brasic N, Roszkowski JJ, Voelkl S, Mackensen A, Kast WM, Le Poole IC, Nishimura MI. Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition. Cancer Immunology, Immunotherapy : Cii. 58: 719-28. PMID 18836717 DOI: 10.1007/S00262-008-0594-2 |
0.698 |
|
| 2009 |
Rubinstein MP, Salem ML, Kadima AN, Nguyen CL, Gillanders WE, Nishimura MI, Cole DJ. Loss of T cell-mediated antitumor immunity after construct-specific downregulation of retrovirally encoded T-cell receptor expression in vivo. Cancer Gene Therapy. 16: 171-83. PMID 18690205 DOI: 10.1038/Cgt.2008.63 |
0.661 |
|
| 2009 |
Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunology, Immunotherapy : Cii. 58: 49-59. PMID 18446337 DOI: 10.1007/S00262-008-0523-4 |
0.371 |
|
| 2009 |
Brusko T, Zhu S, Putnam A, Lee M, McClymont S, Liu W, Nishimura M, Koya R, Tree T, Riley J, Bluestone J. OR.105. Development of Engineered Antigen-specific Human Regulatory T Cells for the Treatment of Type 1 Diabetes by TCR Gene Transfer Clinical Immunology. 131: S42-S43. DOI: 10.1016/J.Clim.2009.03.120 |
0.364 |
|
| 2008 |
Ando T, Mimura K, Johansson CC, Hanson MG, Mougiakakos D, Larsson C, Martins da Palma T, Sakurai D, Norell H, Li M, Nishimura MI, Kiessling R. Transduction with the antioxidant enzyme catalase protects human T cells against oxidative stress. Journal of Immunology (Baltimore, Md. : 1950). 181: 8382-90. PMID 19050255 DOI: 10.4049/Jimmunol.181.12.8382 |
0.779 |
|
| 2008 |
Voelkl S, Moore T, Rehli M, Nishimura M, Fischer K, Mackensen A. Characterization of MHC Class-I Restricted TCRαβ+CD4−CD8− Double-Negative T Cells Recognizing the gp100 Antigen from a Melanoma Patient after gp100 Vaccination Blood. 112: 4905-4905. DOI: 10.1182/Blood.V112.11.4905.4905 |
0.621 |
|
| 2007 |
Deng L, Langley RJ, Brown PH, Xu G, Teng L, Wang Q, Gonzales MI, Callender GG, Nishimura MI, Topalian SL, Mariuzza RA. Structural basis for the recognition of mutant self by a tumor-specific, MHC class II-restricted T cell receptor. Nature Immunology. 8: 398-408. PMID 17334368 DOI: 10.1038/Ni1447 |
0.484 |
|
| 2007 |
McKee MD, Fichera A, Nishimura MI. T cell immunotherapy. Frontiers in Bioscience : a Journal and Virtual Library. 12: 919-32. PMID 17127349 DOI: 10.2741/2114 |
0.533 |
|
| 2007 |
Duval L, Schmidt H, Steiniche T, Kaltoft K, Fode K, Jensen JJ, Soerensen SM, Nishimura MI, von der Maase H. Accumulation of lymphocytes following adoptive transfer of allogeneic T lymphocytes equipped with an HLA-A2 restricted, MART-1 reactive T Cell Receptor Journal of Clinical Oncology. 25: 3050-3050. DOI: 10.1200/jco.2007.25.18_suppl.3050 |
0.589 |
|
| 2006 |
Lyons GE, Moore T, Brasic N, Li M, Roszkowski JJ, Nishimura MI. Influence of human CD8 on antigen recognition by T-cell receptor-transduced cells. Cancer Research. 66: 11455-61. PMID 17145893 DOI: 10.1158/0008-5472.Can-06-2379 |
0.622 |
|
| 2006 |
Oyarbide-Valencia K, van den Boorn JG, Denman CJ, Li M, Carlson JM, Hernandez C, Nishimura MI, Das PK, Luiten RM, Le Poole IC. Therapeutic implications of autoimmune vitiligo T cells. Autoimmunity Reviews. 5: 486-92. PMID 16920575 DOI: 10.1097/00008390-200609001-00070 |
0.668 |
|
| 2006 |
Callender GG, Rosen HR, Roszkowski JJ, Lyons GE, Li M, Moore T, Brasic N, McKee MD, Nishimura MI. Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognition. Hepatology (Baltimore, Md.). 43: 973-81. PMID 16628627 DOI: 10.1002/Hep.21157 |
0.55 |
|
| 2006 |
Duval L, Schmidt H, Kaltoft K, Fode K, Jensen JJ, Sorensen SM, Nishimura MI, von der Maase H. Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1229-36. PMID 16489078 DOI: 10.1158/1078-0432.CCR-05-1485 |
0.473 |
|
| 2006 |
Lyons GE, Roszkowski JJ, Man S, Yee C, Kast WM, Nishimura MI. T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunology, Immunotherapy : Cii. 55: 1142-50. PMID 16374636 DOI: 10.1007/S00262-005-0103-9 |
0.629 |
|
| 2006 |
Kaplan BL, Norell H, Callender GG, Ohlum T, Kiessling R, Nishimura MI. Interferon-gamma renders tumors that express low levels of Her-2/neu sensitive to cytotoxic T cells. Cancer Immunology, Immunotherapy : Cii. 55: 653-62. PMID 16151808 DOI: 10.1007/S00262-005-0050-5 |
0.499 |
|
| 2005 |
Fujii S, Nishimura MI, Lotze MT. Regulatory balance between the immune response of tumor antigen-specific T-cell receptor gene-transduced CD8 T cells and the suppressive effects of tolerogenic dendritic cells. Cancer Science. 96: 897-902. PMID 16367910 DOI: 10.1111/J.1349-7006.2005.00124.X |
0.631 |
|
| 2005 |
Nishimura MI, Roszkowski JJ, Moore TV, Brasic N, McKee MD, Clay TM. Antigen recognition and T-cell biology. Cancer Treatment and Research. 123: 37-59. PMID 16211865 DOI: 10.1007/0-387-27545-2_2 |
0.609 |
|
| 2005 |
McKee MD, Roszkowski JJ, Nishimura MI. T cell avidity and tumor recognition: implications and therapeutic strategies. Journal of Translational Medicine. 3: 35. PMID 16174302 DOI: 10.1186/1479-5876-3-35 |
0.648 |
|
| 2005 |
Kaplan BL, Moore TV, Schreiber K, Callender GG, Schreiber H, Nishimura MI. A new murine tumor model for studying HLA-A2-restricted anti-tumor immunity. Cancer Letters. 224: 153-66. PMID 15911111 DOI: 10.1016/J.Canlet.2004.11.035 |
0.391 |
|
| 2005 |
Roszkowski JJ, Lyons GE, Kast WM, Yee C, Van Besien K, Nishimura MI. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Research. 65: 1570-6. PMID 15735047 DOI: 10.1158/0008-5472.Can-04-2076 |
0.716 |
|
| 2004 |
Langerman A, Callender GG, Nishimura MI. Retroviral transduction of peptide stimulated t cells can generate dual t cell receptor-expressing (bifunctional) t cells reactive with two defined antigens. Journal of Translational Medicine. 2: 42. PMID 15588290 DOI: 10.1186/1479-5876-2-42 |
0.652 |
|
| 2004 |
Rosen HR, Hinrichs DJ, Leistikow RL, Callender G, Wertheimer AM, Nishimura MI, Lewinsohn DM. Cutting edge: identification of hepatitis C virus-specific CD8+ T cells restricted by donor HLA alleles following liver transplantation. Journal of Immunology (Baltimore, Md. : 1950). 173: 5355-9. PMID 15494481 DOI: 10.4049/Jimmunol.173.9.5355 |
0.5 |
|
| 2004 |
Klyushnenkova EN, Ponniah S, Rodriguez A, Kodak J, Mann DL, Langerman A, Nishimura MI, Alexander RB. CD4 and CD8 T-lymphocyte recognition of prostate specific antigen in granulomatous prostatitis. Journal of Immunotherapy (Hagerstown, Md. : 1997). 27: 136-46. PMID 14770085 DOI: 10.1097/00002371-200403000-00007 |
0.477 |
|
| 2003 |
Kaplan BL, Yu DC, Clay TM, Nishimura MI. Redirecting T lymphocyte specificity using T cell receptor genes. International Reviews of Immunology. 22: 229-53. PMID 12745641 DOI: 10.1080/08830180305227 |
0.653 |
|
| 2003 |
Lee KM, Bhawan S, Majima T, Wei H, Nishimura MI, Yagita H, Kumar V. Cutting edge: the NK cell receptor 2B4 augments antigen-specific T cell cytotoxicity through CD48 ligation on neighboring T cells. Journal of Immunology (Baltimore, Md. : 1950). 170: 4881-5. PMID 12734329 DOI: 10.4049/Jimmunol.170.10.4881 |
0.607 |
|
| 2003 |
Roszkowski JJ, Yu DC, Rubinstein MP, McKee MD, Cole DJ, Nishimura MI. CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell. Journal of Immunology (Baltimore, Md. : 1950). 170: 2582-9. PMID 12594285 DOI: 10.4049/Jimmunol.170.5.2582 |
0.695 |
|
| 2003 |
Rubinstein MP, Kadima AN, Salem ML, Nguyen CL, Gillanders WE, Nishimura MI, Cole DJ. Transfer of TCR genes into mature T cells is accompanied by the maintenance of parental T cell avidity. Journal of Immunology (Baltimore, Md. : 1950). 170: 1209-17. PMID 12538678 DOI: 10.4049/Jimmunol.170.3.1209 |
0.645 |
|
| 2003 |
Clay TM, Nishimura MI. Retroviral transfer of T-cell receptor genes into human peripheral blood lymphocytes. Methods in Molecular Biology (Clifton, N.J.). 215: 227-34. PMID 12512302 DOI: 10.1385/1-59259-345-3:227 |
0.49 |
|
| 2002 |
Spiotto MT, Yu P, Rowley DA, Nishimura MI, Meredith SC, Gajewski TF, Fu YX, Schreiber H. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity. 17: 737-47. PMID 12479820 DOI: 10.1016/S1074-7613(02)00480-6 |
0.456 |
|
| 2001 |
Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, Schwartzentruber DJ, Hwu P, Marincola FM, Sherry R, Leitman SF, Rosenberg SA. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 24: 363-73. PMID 11565838 DOI: 10.1097/00002371-200107000-00012 |
0.519 |
|
| 2001 |
Orentas RJ, Roskopf SJ, Nolan GP, Nishimura MI. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide Clinical Immunology. 98: 220-228. PMID 11161978 DOI: 10.1006/Clim.2000.4977 |
0.503 |
|
| 2000 |
McKee MD, Clay TM, Diamond RA, Rosenberg SA, Nishimura MI. Quantitation of T-cell receptor frequencies by competitive polymerase chain reaction: dynamics of T-cell clonotype frequencies in an expanding tumor-infiltrating lymphocyte culture. Journal of Immunotherapy (Hagerstown, Md. : 1997). 23: 419-29. PMID 10916751 DOI: 10.1097/00002371-200007000-00005 |
0.594 |
|
| 2000 |
Ladányi A, Nishimura MI, Rosenberg SA, Yang JC. Tumorigenicity and immunogenicity of murine tumor cells expressing an MHC class II molecule with a covalently bound antigenic peptide. Journal of Immunotherapy (Hagerstown, Md. : 1997). 23: 36-47. PMID 10687136 DOI: 10.1097/00002371-200001000-00006 |
0.545 |
|
| 1999 |
Dudley ME, Nishimura MI, Holt AK, Rosenberg SA. Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. Journal of Immunotherapy (Hagerstown, Md. : 1997). 22: 288-98. PMID 10404430 DOI: 10.1097/00002371-199907000-00002 |
0.429 |
|
| 1999 |
McKee MD, Clay TM, Rosenberg SA, Nishimura MI. Quantitation of T-cell receptor frequencies by competitive PCR: generation and evaluation of novel TCR subfamily and clone specific competitors. Journal of Immunotherapy (Hagerstown, Md. : 1997). 22: 93-102. PMID 10093034 DOI: 10.1097/00002371-199903000-00001 |
0.524 |
|
| 1999 |
Clay TM, Custer MC, Spiess PJ, Nishimura MI. Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer. Pathology & Oncology Research. 5: 3-15. PMID 10079371 DOI: 10.1053/Paor.1999.0003 |
0.558 |
|
| 1999 |
Pieper R, Christian RE, Gonzales MI, Nishimura MI, Gupta G, Settlage RE, Shabanowitz J, Rosenberg SA, Hunt DF, Topalian SL. Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells. The Journal of Experimental Medicine. 189: 757-66. PMID 10049939 DOI: 10.1084/Jem.189.5.757 |
0.64 |
|
| 1998 |
Nishimura MI, Custer MC, Schwarz SL, Parker LL, Mixon A, Clay TM, Yannelli JR, Rosenberg SA. T cell-receptor V gene use by CD4+ melanoma-reactive clonal and oligoclonal T-cell lines. Journal of Immunotherapy (Hagerstown, Md. : 1997). 21: 352-62. PMID 9789197 DOI: 10.1097/00002371-199809000-00003 |
0.682 |
|
| 1997 |
Shilyansky J, Yang JC, Custer MC, Spiess P, Mixon A, Cole DJ, Mulé JJ, Rosenberg SA, Nishimura MI. Identification of a T-cell receptor from a therapeutic murine T-cell clone. Journal of Immunotherapy (Hagerstown, Md. : 1997). 20: 247-55. PMID 9220314 DOI: 10.1097/00002371-199707000-00001 |
0.474 |
|
| 1997 |
Zhai Y, Yang JC, Spiess P, Nishimura MI, Overwijk WW, Roberts B, Restifo NP, Rosenberg SA. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. Journal of Immunotherapy (Hagerstown, Md. : 1997). 20: 15-25. PMID 9101410 DOI: 10.1097/00002371-199701000-00002 |
0.46 |
|
| 1996 |
Loftus DJ, Castelli C, Clay TM, Squarcina P, Marincola FM, Nishimura MI, Parmiani G, Appella E, Rivoltini L. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1((27-35)) Journal of Experimental Medicine. 184: 647-657. PMID 8760818 DOI: 10.1084/Jem.184.2.647 |
0.438 |
|
| 1995 |
Yannelli JR, McConnell S, Parker L, Nishimura M, Robbins P, Yang J, Gamil ME, Kawakami Y. Melanoma tumor-infiltrating lymphocytes derived from four distinct anatomic sites obtained from a single patient: Comparison of functional reactivity and melanoma antigen recognition Journal of Immunotherapy. 18: 263-271. PMID 8680654 |
0.431 |
|
| 1994 |
Nishimura MI, Kawakami Y, Charmley P, O'Neil B, Shilyansky J, Yannelli JR, Rosenberg SA, Hood L. T-cell receptor repertoire in tumor-infiltrating lymphocytes. Analysis of melanoma-specific long-term lines. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 16: 85-94. PMID 7804531 DOI: 10.1097/00002371-199408000-00002 |
0.354 |
|
| 1994 |
Shilyansky J, Nishimura MI, Yannelli JR, Kawakami Y, Jacknin LS, Charmley P, Rosenberg SA. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines. Proceedings of the National Academy of Sciences of the United States of America. 91: 2829-33. PMID 7511820 DOI: 10.1073/Pnas.91.7.2829 |
0.576 |
|
| 1993 |
Kawakami Y, Nishimura MI, Restifo NP, Topalian SL, O'Neil BH, Shilyansky J, Yannelli JR, Rosenberg SA. T-cell recognition of human melanoma antigens. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 14: 88-93. PMID 8280705 DOI: 10.1097/00002371-199308000-00002 |
0.508 |
|
| 1991 |
Nishimura MI, Ostrand-Rosenberg S. Mouse hepa-1 tumor is rejected by H-2db-restricted CTL despite decreased MHC class I antigen expression Cellular Immunology. 136: 414-424. PMID 1908353 DOI: 10.1016/0008-8749(91)90363-G |
0.504 |
|
| Show low-probability matches. |